(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/118507 A2

(51) International Patent Classification:
A61K 31/437 (2006.01) *A61P 25/28* (2006.01)
A61K 31/498 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4985 (2006.01) *A61P 35/00* (2006.01)
A61P 9/00 (2006.01) *A61P 37/00* (2006.01)
A61P 25/04 (2006.01)

(21) International Application Number:
PCT/EP2022/087613

(22) International Filing Date:
22 December 2022 (22.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21217181.3 22 December 2021 (22.12.2021) EP
21217182.1 22 December 2021 (22.12.2021) EP

(71) Applicant: **AUGUSTINE THERAPEUTICS** [BE/BE]; Gaston Geenslaan 1, 3001 Leuven (BE).

(72) Inventors: **CELANIRE, Sylvain**; c/o Augustine Therapeutics, Bio-Incubator Leuven, Gaston Geenslaan 1, 3001 Leuven (BE). **DOS SANTOS CARVALHO, Joao Fernando**; Geldenaaksebaan 266, bus 0201, 3001 Heverlee (BE). **ROMBOUTS, Frederik Jan Rita**; c/o Augustine Therapeutics, Bio-Incubator Leuven, Gaston Geenslaan 1, 3001 Leuven (BE). **SENNHENN, Peter Christian**; Franz-Joseph-Str. 7, 80801 Munich (DE). **CURCIO, Michele**; Dalemstraat 2A, 3060 Bertem (BE). **REIS PEDRO, Joana Catarina**; Dalemstraat 2A, 3060 Bertem (BE).

(74) Agent: **ICOSA EUROPE**; Rue d'Oultremont, 37, 1040 Bruxelles (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2023/118507 A2

(54) **Title:** COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS



(I)

(57) **Abstract:** The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y^1 is a 9- or 10-membered bicyclic heteroaryl, Y^2 is a 5-membered heteroaryl, Z^1 is selected from (C=O)-R^9, S(O)-R^9 and $S(O_2)$-R^9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R^1 and R^9 may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.